Cover Page

Cite item


The article presents the European Guidelines for the Diagnostics and Management of Urticaria (revised in 2013) and new data on the physiopathology of urticaria related to the role of the platelet-activating factor (PAF) activating mast cells, attracting eosinophils and neutrophils, improving vascular permeability (it is more potent than histamine by 1,000 times) and mucosal edema, and increasing the level of pro-inflammatory cytokines. The data promoted the creation of a new rupatadine molecule, which blocks histamine and PAF receptors at the same time improving the therapeutic effect during urticaria treatment as compared to other antihistamine drugs. The author presents the study results confirming the efficacy and safety of rupatadine.

About the authors

A. V. Samtsov

Military Medical Academy named after S.M. Kirov Ministry of Defense of the Russian Federation

Author for correspondence.
Russian Federation


  1. Krapivnica. Klinicheskie rekomendacii. M, 2007, S. 25. [Крапивница. Клинические рекомендации. М, 2007, С. 25.]
  2. Greaves M.Chronic idiopathic urticaria. Curr Opin Allergy Clin lmmunol. 2003; 3: 363-368.
  3. Martina М., Kozel С., Ruth А. et al. Chronic Urticaria: aetiology, management and current and future treatment options. Drugs 2004; 64: 2515-2536.
  4. Magerl М. Urticaria- Classification and Strategies for Diagnosis and Treatment. СМЕ Dermatol 2008; 3: 2-18.
  5. Zuberbier T., Aberer W., Asero R. The EAACI/ GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014; doi: 10.1111/all.12313.
  6. O'Donnell B.F., Lawlor F., Simpson J., Morgan М., Greaves M.W. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997 Feb; 136: 197-201.
  7. Negro-Aivarez J., Miralles-Lüpez J. Chronic idiopathic urticaria treatment. Allergol et lmmunopathol 2001; 29 (4): 129-132.
  8. Кубанов А.А.,Чикин В.В. Лечение больных крапивницей блокатором Н1 гистаминовых рецепторов рупатадином. Вестн дерматол 2014; (3): 116-120
  9. Гущин И.С. Полифункциональная противоаллергическая активность антигистаминного препарата рупатадина. Рос аллергол журн, 2012; (4): 3-15.
  10. Merlos M., Giral M., Balsa D. et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF) J Pharmacol Exp Ther 1997; 280: 114-121.
  11. Mullol J. Rupatadine in Allergic Rhinitis and Chronic Urticaria. Allergy 2008; 63 (Suppl. 87): 5-28.
  12. Merlos M., Giral M., Balsa D., Ferrando R., Queralt M., Puigdemont A. et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther 1997; 280: 114-121.
  13. Dubertret L., Zalupca L., Cristodoulo T., Benea V., Medina I., Fantin S. et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur J Dermatol 2007; 17: 223-228.
  14. Gimenez-Arnau A., Donado E., Arnaiz E., Perez I., Izquierdo I. Fast onset of action of rupatadine in the reduction of pruritus in patients suffering from chronic urticaria: pooled analysis.Allergy 2007; 62 (Suppl 83): 539-546.
  15. Bhanu Prakash Kolasani, Raghunandan Mudium, Narottam Reddy. A comparative study of efficacy and safety of rupatadine versus desloratadine in patients with chronic idiopathic urticaria. Asian Journal of Biomedical and Pharmaceutical Sciences 2013, 3: 42-47.
  16. Dakhale G. et al. Clinical effectiveness and safety of cetirizine versus rupatadine in chronic spontaneous urticaria:a randomized, doubleblind, 6-week trial. Int J Dermatol 2014; 53: 643-649.

Copyright (c) 2014 Samtsov A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies